^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Lovaxin B (diznalimgene lisbac)
i
Other names: OST-HER2, ADXS-HER2 construct vaccine, ADXS31-164, ADXS 31164, ADXS-HER2 construct vaccine, ADXS-cHER2, OST31-164, OST31 164
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OS Therapies
Drug class:
HER2 inhibitor
Related drugs:
10ms
Immunological responses and clinical outcomes in pet dogs with osteosarcoma receiving standard of care therapy and a recombinant Listeria vaccine expressing HER2/neu. (PubMed, Mol Ther)
In conclusion, although ADXS31-164c did not significantly extend DFI or OS, immune responses to ADXS31-164c distinguished elite from short-term survivors. Improvement of immune responses over sequential ADXS31-164c administrations supports a future trial design of recurrent immunizations to improve outcomes of otherwise short-term survivors.
Clinical data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
HER-2 expression
|
Lovaxin B (diznalimgene lisbac)
11ms
AOST-2121: Osteosarcoma Maintenance Therapy With OST31-164 (clinicaltrials.gov)
P2, N=39, Active, not recruiting, George Clinical Pty Ltd | Completed --> Active, not recruiting | Trial completion date: Sep 2023 --> Oct 2027
Enrollment closed • Trial completion date
|
Lovaxin B (diznalimgene lisbac)
Share via
